UnitedHealth's New CFO Cuts Ties with Rival Centene, UNH Stock Up 4.2%

UnitedHealth has appointed Wayne DeVeydt as its new CFO, effective in early September. DeVeydt's departure from Centene Corporation's board was confirmed, and he will not seek a replacement. UnitedHealth is facing regulatory scrutiny, rising medical costs, and declining investor confidence. The company's stock has plunged over 50% year-to-date. The Moderate Buy consensus rating and $318 average stock price target imply a 26.68% upside potential.

UnitedHealth Group Inc. has appointed Wayne DeVeydt as its new Chief Financial Officer (CFO), effective in early September. DeVeydt's departure from Centene Corporation's board was confirmed, and he will not seek a replacement. This move comes amidst significant challenges for UnitedHealth, including regulatory scrutiny, rising medical costs, and declining investor confidence. The company's stock has plunged over 50% year-to-date, reflecting these pressures.

DeVeydt, previously a managing director at Bain Capital and holding key positions at Surgery Partners and Anthem, brings extensive experience in healthcare delivery and insurance. He will replace John Rex, who has served as UnitedHealth's CFO for nearly a decade. DeVeydt's new contract includes a base salary of $1 million plus various lucrative bonuses and stock awards [1].

UnitedHealth is navigating a difficult period. The company has faced rising consumer mistrust, acute regulatory scrutiny, and a tidal wave of medical costs, leading to lower profit forecasts for 2025. The company has made extensive management changes, including replacing its CEO and reshuffling leadership in its operations and divisions [2].

Despite these challenges, analysts remain cautiously optimistic. Piper Sandler maintains its Overweight rating and $280.00 price target on UnitedHealth Group, suggesting the stock is undervalued. UBS reiterated its Buy rating with a price target of $330, while Bernstein SocGen Group adjusted its target to $337, citing a lower earnings starting point for 2025 but remaining optimistic about the company's potential for earnings growth [3].

The Moderate Buy consensus rating and $318 average stock price target imply a 26.68% upside potential, indicating that investors see value in UnitedHealth's strategic turnaround efforts.

References:
[1] https://finance.yahoo.com/news/incoming-unitedhealth-cfo-steps-down-083908156.html
[2] https://news.bloomberglaw.com/health-law-and-business/unitedhealth-hires-new-cfo-wayne-deveydt-from-bain-capital
[3] https://ca.investing.com/news/analyst-ratings/piper-sandler-reiterates-overweight-rating-on-unitedhealth-stock-93CH-4137424